Evrópusambandið - íslenska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxórúbicín hýdróklóríð - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Æxlishemjandi lyf - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - pregabalinum inn - hart hylki - 150 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - b/phuket/3073/2013-líkur stofn (b/phuket/3073/2013, villigerð); a/victoria/2570/2019 (h1n1)pdm09 - líkur stofn (a/victoria/2570/2019, ivr-215); a/darwin/9/2021 (h3n2)- líkur stofn (a/darwin/9/2021, san-010); b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - stungulyf, dreifa í áfylltri sprautu - 15/15/15/15 míkróg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 80 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 25 mg